Publication | Closed Access
Off-label indications for imiquimod
26
Citations
0
References
2009
Year
ImmunologyPharmacotherapyDermatologyAdaptive ArmsImmune SystemImmunotherapyTranslational MedicineOff-label IndicationsExperimental DermatologyLaboratory MedicineOff-label UseRheumatologyAllergyAutoimmune DiseaseClinical DermatologyAutoimmunityDermatopathologySclerodermaMedical DiagnosticsAtopic DermatitisMedicine
Due to the ability of imiquimod (Aldara, 3M Pharmaceuticals) to rapidly and potently stimulate both innate and adaptive arms of the immune system, imiquimod has rapidly been recognized as a potential candidate for off-label use in over 60 conditions as presented in numerous case reports, letters, and small trials. It is our goal to examine and consolidate this impressive body of literature in order to provide the practicing dermatologist with a quick reference of the conditions that have been successfully treated with imiquimod, the dosages used, and the success rates of treatments.